Tag: diffuse large B-cell lymphoma (DLBCL)

March 30, 2022 Off

CHMP Recommends EU Approval of Roche’s Polivy Combination for People with Previously Untreated Diffuse Large B-cell Lymphoma

By Author

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Roche’s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL).

April 18, 2017 Off

FDA grants breakthrough therapy designation to Novartis’s B-cell cancer

By Dino Mustafić

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.